|
1
|
Mahdavifar N, Ghoncheh M, Pakzad R,
Momenimovahed Z and Salehiniya H: Epidemiology, incidence and
mortality of bladder cancer and their relationship with the
development index in the world. Asian Pac J Cancer Prev.
17:381–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klotz L and Brausi MA: World urologic
oncology federation bladder cancer prevention program: A global
initiative. Urol Oncol. 33:25–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu S, Hou J, Zhang H, Wu Y, Hu M, Zhang
L, Xu J, Na R, Jiang H and Ding Q: The evaluation of the risk
factors for non-muscle invasive bladder cancer (NMIBC) recurrence
after transurethral resection (TURBt) in Chinese population. PLoS
One. 10:e01236172014. View Article : Google Scholar
|
|
4
|
Miki T, Nonomura N, Kojima Y, Okuyama A,
Nakano E, Kiyohara H, Fujioka H, Koide T, Wakatsuki A, Kuroda H, et
al: A randomized study on intravesical pirarubicin (THP)
chemoprophylaxis of recurrence after transurethral resection of
superficial bladder cancer. Hinyokika Kiyo. 43:907–912. 1997.(In
Japanese). PubMed/NCBI
|
|
5
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
di Martino E, Tomlinson DC and Knowles MA:
A decade of FGF receptor research in bladder cancer: Past, present,
and future challenges. Adv Urol. 2012:4292132012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Acquaviva J, He S, Zhang C, Jimenez JP,
Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, et al:
FGFR3 translocations in bladder cancer: Differential sensitivity to
HSP90 inhibition based on drug metabolism. Mol Cancer Res.
12:1042–1054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb
A, Jaradat S, Al-Ghazo MA, Matalka I, Musleh H and Haddad Y: FGFR3
mutational status and protein expression in patients with bladder
cancer in a Jordanian population. Cancer Epidemiol. 34:724–732.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poyet C, Hermanns T, Zhong Q, Drescher E,
Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff
EC, et al: Positive fibroblast growth factor receptor 3
immunoreactivity is associated with low-grade non-invasive
urothelial bladder cancer. Oncol Lett. 10:2753–2760. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McConkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guancial EA, Werner L, Bellmunt J, Bamias
A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS,
et al: FGFR3 expression in primary and metastatic urothelial
carcinoma of the bladder. Cancer Med. 3:835–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
L'Hote CG and Knowles MA: Cell responses
to FGFR3 signalling: Growth, differentiation and apoptosis. Exp
Cell Res. 304:417–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katoh M and Nakagama H: FGF receptors:
Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu GS: Role of mitogen-activated protein
kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev.
26:579–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Owens DM and Keyse SM: Differential
regulation of MAP kinase signalling by dual-specificity protein
phosphatases. Oncogene. 26:3203–3213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boutros T, Chevet E and Metrakos P:
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase
regulation: Roles in cell growth, death, and cancer. Pharmacol Rev.
60:261–310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun H, Charles CH, Lau LF and Tonks NK:
MKP-1 (3CH134), an immediate early gene product, is a dual
specificity phosphatase that dephosphorylates MAP kinase in vivo.
Cell. 75:487–493. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Gorospe M, Hutter D, Barnes J, Keyse
SM and Liu Y: Transcriptional induction of MKP-1 in response to
stress is associated with histone H3 phosphorylation-acetylation.
Mol Cell Biol. 21:8213–8224. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bang YJ, Jin HK, Kang SH, Kim JW and Yun
CY: Increased MAPK activity and MKP-1 overexpression in human
gastric adenocarcinoma. Biochem Biophys Res Commun. 250:43–47.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haagenson KK and Wu GS: Mitogen activated
protein kinase phosphatases and cancer. Cancer Biol Ther.
9:337–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Loda M, Capodieci P, Mishra R, Yao H,
Corless C, Grigioni W, Wang Y, Magi-Galluzzi C and Stork PJ:
Expression of mitogen-activated protein kinase phosphatase-1 in the
early phases of human epithelial carcinogenesis. Am J Pathol.
149:1553–1564. 1996.PubMed/NCBI
|
|
22
|
Manzano RG, Montuenga LM, Dayton M, Dent
P, Kinoshita I, Vicent S, Gardner GJ, Nguyen P, Choi YH, Trepel J,
et al: CL100 expression is down-regulated in advanced epithelial
ovarian cancer and its re-expression decreases its malignant
potential. Oncogene. 21:4435–4447. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Xu J, Zhou JY, Liu Y and Wu GS:
Mitogen-activated protein kinase phosphatase-1 is required for
cisplatin resistance. Cancer Res. 66:8870–8877. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang J, Zhou JY and Wu GS: ERK-dependent
MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Cancer Res. 67:11933–11941. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haagenson KK and Wu GS: The role of MAP
kinases and MAP kinase phosphatase-1 in resistance to breast cancer
treatment. Cancer Metastasis Rev. 29:143–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Zhou JY, Kanakapalli D, Buck S, Wu
GS and Ravindranath Y: High level of mitogen-activated protein
kinase phosphatase-1 expression is associated with cisplatin
resistance in osteosarcoma. Pediatr Blood Cancer. 51:754–759. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng L, Chen J, Ma Z, Liu W, Yang F, Yang
Z, Wang K, Wang X, He D, Li L and Zeng J: Capsaicin enhances
anti-proliferation efficacy of pirarubicin via activating TRPV1 and
inhibiting PCNA nuclear translocation in 5637 cells. Mol Med Rep.
13:881–887. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kimura T, Suzuki H, Ohashi T, Asano K,
Kiyota H and Eto Y: The incidence of thanatophoric dysplasia
mutations in FGFR3 gene is higher in low-grade or superficial
bladder carcinomas. Cancer. 92:2555–2561. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ringuette Goulet C, Bernard G, Chabaud S,
Couture A, Langlois A, Neveu B, Pouliot F and Bolduc S:
Tissue-engineered human 3D model of bladder cancer for invasion
study and drug discovery. Biomaterials. 145:233–241. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Camps M, Nichols A and Arkinstall S: Dual
specificity phosphatases: A gene family for control of MAP kinase
function. FASEB J. 14:6–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arakawa M, Nakamura K, Yamada Y, Kato K,
Katsuda R, Tobiume M, Zennami K, Watanabe M, Kato Y, Nishikawa G,
et al: Intravesical administration of pirarubicin against
superficial bladder cancer: Relationship between tumor tissue
concentration and exposure time in the bladder or therapeutic
effect. Exp Ther Med. 2:901–905. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Edmondson R, Broglie JJ, Adcock AF and
Yang L: Three-dimensional cell culture systems and their
applications in drug discovery and cell-based biosensors. Assay
Drug Dev Technol. 12:207–218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Imamura Y, Mukohara T, Shimono Y,
Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S,
Nakatsura T and Minami H: Comparison of 2D- and 3D-culture models
as drug-testing platforms in breast cancer. Oncol Rep.
33:1837–1843. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li C, Singh B, Graves-Deal R, Ma H,
Starchenko A, Fry WH, Lu Y, Wang Y, Bogatcheva G, Khan MP, et al:
Three-dimensional culture system identifies a new mode of cetuximab
resistance and disease-relevant genes in colorectal cancer. Proc
Natl Acad Sci USA. 114:E2852–E2861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chesi M, Nardini E, Brents LA, Schröck E,
Ried T, Kuehl WM and Bergsagel PL: Frequent translocation
t(4;14)(p16.3;q32.3) in multiple myeloma is associated with
increased expression and activating mutations of fibroblast growth
factor receptor 3. Nat Genet. 16:260–264. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cappellen D, De Oliveira C, Ricol D, de
Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and
Radvanyi F: Frequent activating mutations of FGFR3 in human bladder
and cervix carcinomas. Nat Genet. 23:18–20. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hernández S, López-Knowles E, Lloreta J,
Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N and
Real FX: Prospective study of FGFR3 mutations as a prognostic
factor in nonmuscle invasive urothelial bladder carcinomas. J Clin
Oncol. 24:3664–3671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rosenberg JE, Werner L, Bamias A, Choueiri
TK, Schutz FAB, O'Brien RSP, Guancial EA, Ross RW, Berman DM,
Riester M, et al: FGFR3 protein expression and gene mutation in
primary and metastatic urothelial carcinoma (UC) tumors. J Clin
Oncol 30 (15 Suppl). S4572012.
|
|
39
|
Chell V, Balmanno K, Little AS, Wilson M,
Andrews S, Blockley L, Hampson M, Gavine PR and Cook SJ: Tumour
cell responses to new fibroblast growth factor receptor tyrosine
kinase inhibitors and identification of a gatekeeper mutation in
FGFR3 as a mechanism of acquired resistance. Oncogene.
32:3059–3070. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu K, Wang B, Chen Y, Zhou J, Huang J, Hui
K, Zeng J, Zhu J, Zhang K, Li L, et al: DAB2IP regulates the
chemoresistance to pirarubicin and tumor recurrence of non-muscle
invasive bladder cancer through STAT3/Twist1/P-glycoprotein
signaling. Cell Signal. 27:2515–2523. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma G, Pan Y, Zhou C, Sun R, Bai J, Liu P,
Ren Y and He J: Mitogen-activated protein kinase phosphatase 1 is
involved in tamoxifen resistance in MCF7 cells. Oncol Rep.
34:2423–2430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rojo F, González-Navarrete I, Bragado R,
Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C,
Servitja S, Rodriguez-Fanjul V, et al: Mitogen-activated protein
kinase phosphatase-1 in human breast cancer independently predicts
prognosis and is repressed by doxorubicin. Clin Cancer Res.
15:3530–3539. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hu Y, Mintz A, Shah SR, Quinones-Hinojosa
A and Hsu W: The FGFR/MEK/ERK/brachyury pathway is critical for
chordoma cell growth and survival. Carcinogenesis. 35:1491–1499.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brondello JM, Brunet A, Pouysségur J and
Mckenzie FR: The dual specificity mitogen-activated protein kinase
phosphatase-1 and −2 are induced by the p42/p44MAPK cascade. J Biol
Chem. 272:1368–1376. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Franklin CC and Kraft AS: Conditional
expression of the mitogen-activated protein kinase (MAPK)
phosphatase MKP-1 preferentially inhibits p38 MAPK and
stress-activated protein kinase in U937 cells. J Biol Chem.
272:16917–16923. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao Q, Shepherd EG, Manson ME, Nelin LD,
Sorokin A and Liu Y: The role of mitogen-activated protein kinase
phosphatase-1 in the response of alveolar macrophages to
lipopolysaccharide: Attenuation of proinflammatory cytokine
biosynthesis via feedback control of p38. J Biol Chem.
280:8101–8108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Takeuchi H, Taoka R, Mmeje CO, Jinesh GG,
Safe S and Kamat AM: CDODA-Me decreases specificity protein
transcription factors and induces apoptosis in bladder cancer cells
through induction of reactive oxygen species. Urol Oncol.
34:337.e11–e18. 2016. View Article : Google Scholar
|
